en · de · es · fr · pt
aod-9604-notes.peptides7250.com › Topic › Regulation And Detection Context — 2026 Update

Regulation And Detection Context — 2026 Update

By Editorial Desk · published 2026-07-09 · last reviewed 2026-07-29 · Topic

The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-07-29. Anything still debated is marked as such rather than presented as settled.

Regulation and Detection Context

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusProhibited in sportListed by WADA under peptide hormones
WADA classS2Peptide hormones, growth factors, related substances, and mimetics
Approved therapeutic useNot establishedClinical research did not lead to broad marketing approval
Common detection methodLC-MS/MSLiquid chromatography-tandem mass spectrometry
Sample preparationExtraction and enrichmentImmunoaffinity or solid-phase extraction may be used

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Related pages on this site

Handling, Analysis, and Quality Control

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Notes from published material

=== Elderly === Additional caution is required in the elderly, as they are more sensitive to the pharmacological effects of benzodiazepines, metabolise them more slowly, and are more prone to adverse effects, including drowsiness, amnesia (especially anterograde amnesia), ataxia, hangover effects, confusion, and falls.

== History == Dated back to 1956, the first protein modified transition metal catalyst was documented. The Palladium(II) salt was absorbed onto silk fibroin fiber, reduced by hydrogen to get the first reported ArM, which can catalyze asymmetric hydrogenation. This work was not reproducible, but it is considered to be the first work in the field of artificial metalloenzymes. At that time, the major challenge that blocked further studies was underdeveloped protein production and purification technology. The first attempt to anchor an abiotic metal center onto a protein was reported by Whitesides et al. using biotin-avidin interaction, making an artificial hydrogenase. The presence of avidin can significantly increase the catalytic capacity of Rhodium(I) cofactor in aqueous phosphate buffer. Another pioneering work was conducted by Kaiser et al. where carboxypeptidase A (CPA) was repurposed into an oxidase by substituting Zn(II) center by Cu(II), for the oxidation of ascorbic acid. The real potential of ArMs was unleashed when recombinant protein production was developed, namely in 1997 Distefano and Davies reported a scaffold modification of a recombinant adipocyte lipid-binding protein (ALBP) with iodoacetamido-1,10-phenanthroline coordinating Cu(II) for the stereoselective hydrolysis of racemic esters.

The WAV, run by the Ministry of Defence, recruited and trained female personnel for the WAAS and the WAMS, which respectively came under the Air and Defence Ministries. According to the official statement announcing their formation, the services' purpose was "to substitute women for men wherever necessary and practicable throughout the military and air forces within Southern Rhodesia." Recruitment for the women's services began in June 1941. Most volunteers were married women, many of them the wives of military men. The air and military services both offered a wide variety of positions. In addition to jobs as typists, clerks, caterers and the like, women served as drivers and in the stores and workshops. Many of the women in the air service did skilled work, checking flying instruments, testing parts and doing minor repairs. The women of the Auxiliary Police Service served as BSAP officers both in stations and on the streets. Members of Southern Rhodesia's white female population who did not join the forces still contributed to the war in various ways. Women worked in munitions factories and engineering workshops in Salisbury and Bulawayo. The Women's National Service League, which thousands of women joined before the war even started, revived the role white Rhodesian women had played in World War I, sending the colony's servicemen overseas parcels containing warm clothes, newspapers, razor blades, soap, food and minor luxuries such as sweets, tobacco and novels. Efforts such as these did much to keep the troops' morale up.

Sources: en.wikipedia.org

Further detail

Lee (1992), former Associated Press bureau chief in Pyongyang and Seoul Jori Finkel (1992), art reporter for The New York Times and Los Angeles Times Olivier Knox (1992), chief Washington correspondent for SiriusXM and former president of the White House Correspondents' Association Jim Frederick (1993), author and journalist Russell Gold (1993), journalist for The Wall Street Journal and Pulitzer Prize-finalist Michael Rothfeld (1993), journalist for The Wall Street Journal and winner of the 2019 Pulitzer Prize for National Reporting Brad Stone (1993), journalist for Bloomberg Business Anne Kornblut (1994), correspondent for The Washington Post, winner of the 2014 Pulitzer Prize for Public Service Joshua Prager (1994), journalist and author who writes on historical secrets Jodi Kantor (1996), writer and former editor on culture and politics for The New York Times, winner of the 2018 Pulitzer Prize for Public Service Harriet Ryan (1996), journalist and winner of the 2019 Pulitzer Prize for Investigative Reporting Robin Shulman (1996), freelance journalist Kate Kelly (1997), journalist for The New York Times Nicholas Kulish (1997), Berlin bureau chief for The New York Times and novelist Patrick Radden Keefe (1999), writer and investigative journalist David Epstein (2002), investigative reporter at ProPublica and author of the New York Times bestseller The Sports Gene Nick Schifrin (2002), Al Jazeera America's Middle East correspondent Ben Casselman (2003), economics reporter at The New York Times Jonah Lehrer (2003), former writer for The New Yorker discharged for falsifying quotes Poppy Harlow (2005), correspondent for CNN Sarah Maslin Nir (2005), investigative journalist for The New York Times Marc Tracy (2007), journalist for The New York Times, recipient of a 2011 National Magazine Award and a 2012 National Jewish Book Award Linette Lopez (2008), journalist for Business Insider involved in the December 15, 2022 Twitter suspensions Nellie Bowles (2010), technology journalist for The New York Times Cecilia Reyes (2015), winner of the Pulitzer Prize for Investigative Reporting in 2022

The Green Book, formally titled Quantities, Units and Symbols in Physical Chemistry, is a compilation of terms and symbols widely used in the field of physical chemistry. It also includes a table of physical constants, tables listing the properties of elementary particles, chemical elements, and nuclides, and information about conversion factors that are commonly used in physical chemistry. The most recent is the third edition (ISBN 978-0-85404-433-7), originally published by IUPAC in 2007. A second printing of the third edition was released in 2008; this printing made several minor revisions to the 2007 text. A third printing of the third edition was released in 2011. The text of the third printing is identical to that of the second printing.

== Veterinary use == In veterinary anesthesia, butorphanol (trade name: Torbugesic) is widely used as a sedative and analgesic in dogs, cats and horses. For sedation, it may be combined with tranquilizers such as alpha-2 agonists (medetomidine), benzodiazepines, or acepromazine in dogs, cats and exotic animals. It is frequently combined with xylazine or detomidine in horses. Butorphanol may be administered intravenously, intramuscularly, subcutaneously, or per os. Intramuscular and subcutaneous administration may cause pain. Oral tablets have poor bioavailability and are not suitable for analgesia. Instranasal usage has been reported in parrots and rabbits. Butorphanol when administered at 0.4 mg/kg given IV/IM does not provide sufficient post-operative analgesia for laparotomy and shoulder arthrotomy in dogs and ovariohysterectomy in bitches. When butorphanol is used as a sedative in dogs—either on its own or with dexmedetomidine—it provides fast sedation and is faster than sedation with methadone. Butorphanol is also approved as an antitussive in the dog. Butorphanol has antiemetic properties, which counteracts the nausea-induced by dexmedetomidine. Butorphanol's antiemetic properties are greater than that of buprenorphine. Doses of 0.1–0.4 mg/kg IM in cats provides appropriate sedation but greater sedation may be achieved with full μ-opioid receptor agonists. Butorphanol when administered alongside meloxicam, lidocaine, and dexmedetomidine provides appropriate analgesia for orchidectomy and reduces the mean alveolar concentration for isoflurane more than buprenorphine.

Sources: en.wikipedia.org

Supporting material

== Synthetic insecticides == Insecticides are most usefully categorised according to their modes of action. The insecticide resistance action committee (IRAC) lists 30 modes of action plus unknowns. There can be several chemical classes of insecticide with the same mode or action. IRAC lists 56 chemical classes plus unknowns. The mode of action describes how the insecticide kills or inactivates a pest.

== Production == Plans to create a Nick Fury live action production were circulated as early as September 1986, but it was not until mid-May 1995 that Fox Broadcasting announced the acquisition from New World Entertainment of a Nick Fury series pilot, to be broadcast in 1996. The film was originally sold to Paramount Pictures, with Debra Hill and Lynda Obst as producers, Greg Pruss to write and Stephen Herek originally attached to direct. The teleplay was written by David S. Goyer several years before the film was made, and Goyer was not otherwise involved as he was working on the television series Sleepwalkers. Despite some misgivings within the studio, the producers cast David Hasselhoff in the lead role "to give SHIELD some recognizable star power". The production also markedly "respected and utilized the comic roots of the project", incorporating "a who's who of the Marvel spy scene" and retaining details such as Fury's eyepatch. Goyer was not enthusiastic about the casting of David Hasselhoff, but in hindsight said, "Hasselhoff turned out to be the best thing in it. He got the joke. The script was meant to be very tongue in cheek, and Hasselhoff understood that. Goyer described the film overall as "pretty mediocre". Hasselhoff was reportedly signed for five additional Nick Fury television films, which did not materialize. Shooting for the project occurred between May and June 1997 in Vancouver, British Columbia, Canada.

Pakistan is a member of the United Nations, the Shanghai Cooperation Organisation, the Organisation of Islamic Cooperation, the Commonwealth of Nations, the South Asian Association for Regional Cooperation, and the Islamic Military Counter-Terrorism Coalition, and is designated as a major non-NATO ally by the United States.

== Side effects == Calcium gluconate side effects include nausea, constipation, and upset stomach. Rapid intravenous injections of calcium gluconate may cause hypercalcemia, which can result in vasodilation, cardiac arrhythmias, decreased blood pressure, and bradycardia. Extravasation of calcium gluconate can lead to cellulitis. Intramuscular injections may lead to local necrosis and abscess formation. It is also reported that this form of calcium increases renal plasma flow, urine production, sodium excretion, glomerular filtration rate, and prostaglandin E2 and F1-alpha levels.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 banned in sport?

Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.

How is AOD-9604 detected?

Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.

Does AOD-9604 have approved therapeutic uses?

No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network